Central Nervous System

SS 13 - CNS 2 - Gliomas

92 - Elevated MGMT Gene Expression Is Independently Associated With Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma

Monday, October 22
10:45 AM - 10:55 AM
Location: Room 004

Elevated MGMT Gene Expression Is Independently Associated With Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma
J. Fleming1, J. McElroy1, E. H. Bell1, S. M. Chang2, E. F. Youssef3, G. K. Hunter4, W. A. Yung5, S. P. Howard6, J. A. Bovi7, J. P. Bahary8, H. A. Shih9, R. A. Rabinovitch10, Y. Chen11, P. Zhang12, and A. Chakravarti13; 1The Ohio State University Comprehensive Cancer Center, Columbus, OH, 2University of California San Francisco Medical Center-Mount Zion, San Francisco, CA, 3Saint Joseph's Hospital and Medical Center accruals Arizona Oncology Services Foundation, Phoenix, AZ, 4Intermountain Medical Center, Murray, UT, 5MD Anderson Cancer Center, Houston, TX, 6University of Wisconsin Hospital, Madison, WI, 7Froedtert and The Medical College of Wisconsin, Milwaukee, WI, 8Centre Hospitalier de L'Universite de Montreal, Montreal, QC, Canada, 9Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 10University of Colorado Cancer Center, Aurora, CO, 11University of Rochester, Rochester, NY, 12NRG Oncology Statistics and Data Management Center, Philadelphia, PA, 13Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Purpose/Objective(s): This study sought to determine the prognostic significance of MGMT gene expression in NRG Oncology/RTOG 9813.

Materials/Methods: Gene expression data were generated using a transcriptome array on 76 patients from NRG Oncology/RTOG 9813. The MGMT-STP27 prediction model was used to calculate MGMT promoter methylation status from methylation probe data. Univariate (UVAs) and multivariate analyses (MVAs) were conducted using the Cox proportional hazards model and the log-rank test, to determine the effect of MGMT expression as a continuous variable on progression-free survival (PFS) and overall survival (OS). Patient pre-treatment characteristics and treatment assignment were taken into consideration as covariates for the MVAs.

Results: Upon UVAs, elevated MGMT gene expression was significantly associated with worse OS (HR = 1.56; 95% CI (1.17-2.08); p = 0.003) and PFS (HR = 1.39; 95% CI (1.06-1.82); p = 0.019). Models with time-varying effects were used for MVAs due to concerns over the proportional hazards assumption and included the following variables: MGMT gene expression, MGMT promoter methylation, age, IDH mutation, surgery, and KPS. Elevated MGMT gene expression was significantly associated with worse OS (HR = 1.74 95% CI (1.02-2.97); p = 0.043) for its long-term effect. Similarly for PFS, including MGMT promoter methylation, age and IDH mutation, elevated MGMT gene expression was significantly associated with worse PFS (HR = 2.34 for long-term effect; 95% CI (1.22-4.49); p = 0.01). This effect was also similar when MGMT promoter methylation was not included in the MVAs.

Conclusion: Elevated MGMT gene expression was found to be an independent prognostic biomarker in anaplastic astrocytomas treated with RT plus TMZ or RT plus NU independent of MGMT methylation status. This is the first study, to our knowledge, to identify the significance of MGMT gene expression on OS, independent of MGMT promoter methylation, in a phase III study of anaplastic glioma patients using rigorous MVAs. Validation of the prognostic significance of MGMT gene expression is ongoing as well as our efforts to increase sample size.

Author Disclosure: J. Fleming: None. J. McElroy: Employee; The Ohio State University. E.H. Bell: None. E.F. Youssef: None. G.K. Hunter: None. W. Yung: None. J. Bahary: Independent Contractor; centre hospitalier de l'université de montreal. vice chair for canadian affairs; NRG. H.A. Shih: Employee; Dartmouth Hitchcock. Honoraria; UpToDate. Chief, CNS & Eye Radiat Oncol Services; Massachusetts General Hospital. Associate Medical Director; MGH Proton Therapy Center. Associate Director; Harvard Radiation Oncology Program. R. Rabinovitch: Consultant; Best Doctors. A. Chakravarti: None.

Send Email for Jessica Fleming


Assets

92 - Elevated MGMT Gene Expression Is Independently Associated With Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Elevated MGMT Gene Expression Is Independently Associated With Worse Overall Survival in NRG Oncology/RTOG 9813: A Phase III Study of Radiation Therapy (RT) and Temozolomide (TMZ) Versus RT and Nitrosourea (NU) in Anaplastic Grade III Glioma